NTII starts Xerecept Phase III

Neurobiological Technologies (NTII) started the Phase III Acute trial of Xerecept corticotropin-releasing factor plus dexamethasone to treat peritumoral brain edema. The primary endpoint of the 120-patient trial is a reduction in neurological symptoms after two weeks. NTII expects to complete the double-blind trial in the first quarter of 2007 and to submit an NDA by mid-2007. ...